Most melanomas (≈50%) harbour mutations in the kinase BRAF (mostly BRAFV600E) that hyperactivate the mitogen-activated protein kinase (MAPK) pathway (RAS-BRAF-MEK-ERK) [11,12]. Here, BRAF is linked to melanoma.